Mixed bag? Biogen's aducanumab shows continued dose-correlation
This article was originally published in Scrip
Biogen reported data from the 6mg/kg cohort of its PRIME trial of aducanumab at the Alzheimer's Association International Conference (AAIC) on 22 July that will likely leave investors itching for more clarity. The data continue to show dose correlation in efficacy, but safety issues persist at the mid-range dose as well.
You may also be interested in...
Alzheimer's disease is a common and growing global menace that threatens health care budgets, but if a cure was ever found demand for the remedy it would likely swamp payer resources.
The reasons behind Lilly's latest clinical failure had much less to do with the indication and more to do with repeating the past mistakes of Inspire and Sunesis. Unfortunately, that same die has already been cast for the trials of Biogen and Ophthotech that are due to report imminently.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.